Cargando…

592. Antimicrobial Utilization in Solid Organ Transplant Recipients 12-Months Post-Transplantation

BACKGROUND: Antimicrobials are widely used in solid organ transplant recipients (SOTr). Yet, antimicrobial utilization in the transplant (TP) population is not well characterized. National Healthcare Safety Network antimicrobial use (NHSN-AU) does not provide data specific to SOTr. This study sought...

Descripción completa

Detalles Bibliográficos
Autores principales: Parraga Acosta, Tommy J, Greenlee, Sage, Makowski, Charles, Kenney, Rachel, Mayur, Ramesh, Alangaden, George J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644159/
http://dx.doi.org/10.1093/ofid/ofab466.790
_version_ 1784610021915492352
author Parraga Acosta, Tommy J
Greenlee, Sage
Makowski, Charles
Kenney, Rachel
Mayur, Ramesh
Alangaden, George J
author_facet Parraga Acosta, Tommy J
Greenlee, Sage
Makowski, Charles
Kenney, Rachel
Mayur, Ramesh
Alangaden, George J
author_sort Parraga Acosta, Tommy J
collection PubMed
description BACKGROUND: Antimicrobials are widely used in solid organ transplant recipients (SOTr). Yet, antimicrobial utilization in the transplant (TP) population is not well characterized. National Healthcare Safety Network antimicrobial use (NHSN-AU) does not provide data specific to SOTr. This study sought to describe inpatient antibiotic use among SOTr up to 1-year post-TP. METHODS: A cross-sectional study was performed of all SOTr who received a TP between January 2015 to December 2016. Demographics, TP type, antibiotic use variables, hospital days, and Clostridioides difficile infection (CDI) are described. Inpatient antibiotic administration was measured for 365 days starting from date of TP surgery. Automated data generated for NHSN-AU reporting was utilized, and SOTr data was abstracted by cross-matching with the transplant database. Transplant-patient days was used as the denominator for metrics. Variables included duration of therapy (DOT), DOT/1000 patient days, antimicrobial free days (inpatient days no antimicrobials were administered), and NHSN-AU reporting targets of anti-methicillin resistant S. aureus (MRSA), broad spectrum, and high-risk CDI agents. Data was analyzed using descriptive statistics via Microsoft Excel®. RESULTS: A total of 530 SOTr were analyzed. Baseline characteristics are shown in Table 1. Median age was 61, male gender 64%, median Charlson Comorbidity Index was 5. Kidney TP (43%), liver TP (32%), lung (9%) and heart (8%) were most common TP types. Among these four TP types: Lung TP had the highest median DOT (13 days), DOT/1000 patient days (6.6) and ratio of DOT/total patient (1.9) (Table 2). Liver TP had the most antimicrobial free days (34%). Proportionally, anti-MRSA agents use was highest in thoracic TP (lung/heart), broad-spectrum agent use was common in all but kidney TPs, and high-risk CDI agents use was highest among kidney TP (Table 3). A total of 34 SOTr had CDI, 76% in kidney/liver TPs. [Image: see text] Table 1. Antimicrobial usage and SOT - ID Week 2021 [Image: see text] Table 2. Antimicrobial usage and SOT - ID Week 2021 [Image: see text] Table 3. Antimicrobial usage and SOT - ID Week 2021 CONCLUSION: Our study provides preliminary and important data of inpatient antibiotic utilization specifically in SOTr, generated using automated NHSN-AU data cross-matched to transplant database. These metrics can be utilized to promote antimicrobial stewardship efforts directed to specific TP types. DISCLOSURES: Rachel Kenney, PharmD, Medtronic, Inc. (Other Financial or Material Support, spouse is an employee and shareholder)
format Online
Article
Text
id pubmed-8644159
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86441592021-12-06 592. Antimicrobial Utilization in Solid Organ Transplant Recipients 12-Months Post-Transplantation Parraga Acosta, Tommy J Greenlee, Sage Makowski, Charles Kenney, Rachel Mayur, Ramesh Alangaden, George J Open Forum Infect Dis Poster Abstracts BACKGROUND: Antimicrobials are widely used in solid organ transplant recipients (SOTr). Yet, antimicrobial utilization in the transplant (TP) population is not well characterized. National Healthcare Safety Network antimicrobial use (NHSN-AU) does not provide data specific to SOTr. This study sought to describe inpatient antibiotic use among SOTr up to 1-year post-TP. METHODS: A cross-sectional study was performed of all SOTr who received a TP between January 2015 to December 2016. Demographics, TP type, antibiotic use variables, hospital days, and Clostridioides difficile infection (CDI) are described. Inpatient antibiotic administration was measured for 365 days starting from date of TP surgery. Automated data generated for NHSN-AU reporting was utilized, and SOTr data was abstracted by cross-matching with the transplant database. Transplant-patient days was used as the denominator for metrics. Variables included duration of therapy (DOT), DOT/1000 patient days, antimicrobial free days (inpatient days no antimicrobials were administered), and NHSN-AU reporting targets of anti-methicillin resistant S. aureus (MRSA), broad spectrum, and high-risk CDI agents. Data was analyzed using descriptive statistics via Microsoft Excel®. RESULTS: A total of 530 SOTr were analyzed. Baseline characteristics are shown in Table 1. Median age was 61, male gender 64%, median Charlson Comorbidity Index was 5. Kidney TP (43%), liver TP (32%), lung (9%) and heart (8%) were most common TP types. Among these four TP types: Lung TP had the highest median DOT (13 days), DOT/1000 patient days (6.6) and ratio of DOT/total patient (1.9) (Table 2). Liver TP had the most antimicrobial free days (34%). Proportionally, anti-MRSA agents use was highest in thoracic TP (lung/heart), broad-spectrum agent use was common in all but kidney TPs, and high-risk CDI agents use was highest among kidney TP (Table 3). A total of 34 SOTr had CDI, 76% in kidney/liver TPs. [Image: see text] Table 1. Antimicrobial usage and SOT - ID Week 2021 [Image: see text] Table 2. Antimicrobial usage and SOT - ID Week 2021 [Image: see text] Table 3. Antimicrobial usage and SOT - ID Week 2021 CONCLUSION: Our study provides preliminary and important data of inpatient antibiotic utilization specifically in SOTr, generated using automated NHSN-AU data cross-matched to transplant database. These metrics can be utilized to promote antimicrobial stewardship efforts directed to specific TP types. DISCLOSURES: Rachel Kenney, PharmD, Medtronic, Inc. (Other Financial or Material Support, spouse is an employee and shareholder) Oxford University Press 2021-12-04 /pmc/articles/PMC8644159/ http://dx.doi.org/10.1093/ofid/ofab466.790 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Parraga Acosta, Tommy J
Greenlee, Sage
Makowski, Charles
Kenney, Rachel
Mayur, Ramesh
Alangaden, George J
592. Antimicrobial Utilization in Solid Organ Transplant Recipients 12-Months Post-Transplantation
title 592. Antimicrobial Utilization in Solid Organ Transplant Recipients 12-Months Post-Transplantation
title_full 592. Antimicrobial Utilization in Solid Organ Transplant Recipients 12-Months Post-Transplantation
title_fullStr 592. Antimicrobial Utilization in Solid Organ Transplant Recipients 12-Months Post-Transplantation
title_full_unstemmed 592. Antimicrobial Utilization in Solid Organ Transplant Recipients 12-Months Post-Transplantation
title_short 592. Antimicrobial Utilization in Solid Organ Transplant Recipients 12-Months Post-Transplantation
title_sort 592. antimicrobial utilization in solid organ transplant recipients 12-months post-transplantation
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644159/
http://dx.doi.org/10.1093/ofid/ofab466.790
work_keys_str_mv AT parragaacostatommyj 592antimicrobialutilizationinsolidorgantransplantrecipients12monthsposttransplantation
AT greenleesage 592antimicrobialutilizationinsolidorgantransplantrecipients12monthsposttransplantation
AT makowskicharles 592antimicrobialutilizationinsolidorgantransplantrecipients12monthsposttransplantation
AT kenneyrachel 592antimicrobialutilizationinsolidorgantransplantrecipients12monthsposttransplantation
AT mayurramesh 592antimicrobialutilizationinsolidorgantransplantrecipients12monthsposttransplantation
AT alangadengeorgej 592antimicrobialutilizationinsolidorgantransplantrecipients12monthsposttransplantation